13 November 2023
13 November 2023
Following the three-month FDA review delay, Valneva’s live-attenuated chikungunya vaccine, Ixchiq, received accelerated approval.
An oral small-molecule KRASG12C inhibitor, Krazati penetrates the central nervous system.
The latest development is based on positive data from the Phase III KEYNOTE-966 clinical trial.
At the BIO-Europe conference, experts discussed remaining challenges in AI healthcare interventions.
Following the closure of the deal, Forge will function as a fully consolidated Ajinomoto subsidiary.
The latest funding brings the total investment in the programmes since April 2022 to £421m.
At the FT Global Pharma and Biotech Summit in London, various industry players shared their thoughts on technological and regulatory advancements.
An upcoming two-day event will host talks on the impact of new technology on oncology trials and smaller biotechs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.
Give your business an edge with our leading industry insights.
